ENGOT-Ov65/KEYNOTE-B96: Phase III, Randomized, Double-Blind Study Of Pembrolizumab Vs Placebo Plus Paclitaxel With Optional Bevacizumab For Platinum-Resistant Recurrent Ovarian Cancer
dc.contributor.author | Colombo, N. | |
dc.contributor.author | Coleman, R. L. | |
dc.contributor.author | Wu, X. | |
dc.contributor.author | Kose, F. | |
dc.contributor.author | Wenham, R. | |
dc.contributor.author | Sebastianelli, A. | |
dc.contributor.author | Hasegawa, K. | |
dc.contributor.author | Zsiros, E. | |
dc.contributor.author | Rouge, T. De La Motte | |
dc.contributor.author | Bidzinski, M. | |
dc.contributor.author | McNeish, I. | |
dc.contributor.author | Sehouli, J. | |
dc.contributor.author | Korach, J. | |
dc.contributor.author | Debruyne, P. R. | |
dc.contributor.author | Kim, J-W. | |
dc.contributor.author | De Melo, A. C. | |
dc.contributor.author | Peng, X. | |
dc.contributor.author | Bogusz, A. M. | |
dc.contributor.author | Yamada, K. | |
dc.contributor.author | Monk, B. J. | |
dc.date.accessioned | 2022-12-19T07:25:45Z | |
dc.date.available | 2022-12-19T07:25:45Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 0923-7534 | en_US |
dc.identifier.issue | S400 | en_US |
dc.identifier.startpage | S401 | en_US |
dc.identifier.uri | https://reader.elsevier.com/reader/sd/pii/S0923753422007475?token=FF8368913AFE07B7B27DE123C04BD2F1633BBD9FEEFA29DFEB4FCD09F08399C552B8F5EFD2205FC9C9DC7CACA5507110&originRegion=eu-west-1&originCreation=20221219072044 | |
dc.identifier.uri | http://hdl.handle.net/11727/8330 | |
dc.identifier.volume | 33 | en_US |
dc.identifier.wos | 000814982500045 | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1016/j.annonc.2022.04.062 | en_US |
dc.relation.journal | ANNALS OF ONCOLOGY | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.title | ENGOT-Ov65/KEYNOTE-B96: Phase III, Randomized, Double-Blind Study Of Pembrolizumab Vs Placebo Plus Paclitaxel With Optional Bevacizumab For Platinum-Resistant Recurrent Ovarian Cancer | en_US |
dc.type | conferenceObject | en_US |